Calamos Advisors LLC Gilead Sciences, Inc. Transaction History

Calamos Advisors LLC

$16.1 Billion
Q3 2024

A detailed history of Calamos Advisors LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Calamos Advisors LLC holds 232,271 shares of GILD stock, worth $20.9 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares

232,271

Previous 237,942 2.38%

Holding current value

$20.9 Million

Previous $16.3 Million 19.25%

% of portfolio

0.12%

Previous 0.1%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 07, 2024	SELL	$66.59 - $83.99 $377,631 - $476,307	-5,671 Reduced 2.38%	232,271 $19.5 Million
Q2 2024 Jul 25, 2024	SELL	$63.15 - $72.88 $549,594 - $634,274	-8,703 Reduced 3.53%	237,942 $16.3 Million
Q1 2024 May 08, 2024	SELL	$71.58 - $87.29 $441,863 - $538,841	-6,173 Reduced 2.44%	246,645 $18.1 Million
Q4 2023 Jan 31, 2024	SELL	$73.27 - $83.09 $349,278 - $396,090	-4,767 Reduced 1.85%	252,818 $20.5 Million
Q3 2023 Oct 25, 2023	SELL	$73.94 - $80.67 $11.3 Million - $12.3 Million	-152,623 Reduced 37.21%	257,585 $19.3 Million
Q2 2023 Jul 28, 2023	BUY	$76.01 - $86.7 $8,589 - $9,797	113 Added 0.03%	410,208 $31.6 Million
Q1 2023 May 03, 2023	SELL	$77.31 - $88.08 $2.46 Million - $2.8 Million	-31,768 Reduced 7.19%	410,095 $34 Million
Q4 2022 Jan 25, 2023	BUY	$62.32 - $89.47 $3.25 Million - $4.67 Million	52,186 Added 13.39%	441,863 $0
Q3 2022 Oct 24, 2022	BUY	$59.54 - $68.01 $22,625 - $25,843	380 Added 0.1%	389,677 $24 Million
Q2 2022 Aug 01, 2022	BUY	$57.72 - $65.01 $549,032 - $618,375	9,512 Added 2.5%	389,297 $24.1 Million
Q1 2022 May 03, 2022	BUY	$57.92 - $72.58 $2.6 Million - $3.25 Million	44,833 Added 13.38%	379,785 $22.6 Million
Q4 2021 Feb 01, 2022	BUY	$64.88 - $73.64 $714,847 - $811,365	11,018 Added 3.4%	334,952 $24.3 Million
Q3 2021 Oct 26, 2021	BUY	$67.69 - $73.03 $1.73 Million - $1.86 Million	25,507 Added 8.55%	323,934 $22.6 Million
Q2 2021 Jul 22, 2021	BUY	$63.47 - $69.35 $3.6 Million - $3.93 Million	56,738 Added 23.48%	298,427 $20.6 Million
Q1 2021 Apr 12, 2021	BUY	$60.0 - $68.46 $357,300 - $407,679	5,955 Added 2.53%	241,689 $15.6 Million
Q4 2020 Jan 27, 2021	SELL	$56.65 - $64.55 $458,185 - $522,080	-8,088 Reduced 3.32%	235,734 $13.7 Million
Q3 2020 Oct 26, 2020	SELL	$62.1 - $78.08 $11.3 Million - $14.2 Million	-182,099 Reduced 42.75%	243,822 $15.4 Million
Q2 2020 Jul 27, 2020	SELL	$72.34 - $84.0 $8.43 Million - $9.79 Million	-116,560 Reduced 21.49%	425,921 $32.8 Million
Q1 2020 Apr 28, 2020	BUY	$62.63 - $80.22 $305,947 - $391,874	4,885 Added 0.91%	542,481 $40.6 Million
Q4 2019 Jan 15, 2020	SELL	$61.62 - $67.78 $267,800 - $294,571	-4,346 Reduced 0.8%	537,596 $34.9 Million
Q3 2019 Oct 21, 2019	BUY	$62.51 - $69.0 $1.46 Million - $1.62 Million	23,419 Added 4.52%	541,942 $34.3 Million
Q2 2019 Aug 07, 2019	SELL	$61.87 - $69.38 $2.76 Million - $3.1 Million	-44,661 Reduced 7.93%	518,523 $35 Million
Q1 2019 Apr 12, 2019	BUY	$62.53 - $70.05 $182,087 - $203,985	2,912 Added 0.52%	563,184 $36.6 Million
Q4 2018 Jan 24, 2019	BUY	$60.54 - $79.0 $2.02 Million - $2.63 Million	33,331 Added 6.33%	560,272 $35 Million
Q3 2018 Oct 22, 2018	BUY	$71.28 - $78.92 $13.4 Million - $14.8 Million	187,717 Added 55.34%	526,941 $40.7 Million
Q2 2018 Jul 17, 2018	BUY	$64.88 - $75.68 $1.18 Million - $1.38 Million	18,191 Added 5.67%	339,224 $24 Million
Q1 2018 Apr 13, 2018	BUY	$72.84 - $88.8 $377,748 - $460,516	5,186 Added 1.64%	321,033 $24.2 Million
Q4 2017 Feb 13, 2018	SELL	$71.15 - $83.52 $212,525 - $249,474	-2,987 Reduced 0.94%	315,847 $22.6 Million
Q3 2017 Oct 25, 2017	BUY	$72.11 - $85.47 $728,166 - $863,076	10,098 Added 3.27%	318,834 $25.8 Million
Q2 2017 Aug 09, 2017	BUY	N/A	308,736	308,736 $21.9 Million

Others Institutions Holding GILD

# of Institutions

1,923

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $113B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Calamos Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Calamos Advisors LLC with notifications on news.

Account

Calamos Advisors LLC Gilead Sciences, Inc. Transaction History